It would be important in future studies to test whether alternative therapies in development, which target apoCIII and angiopoietin-related protein 3 and lower not only triglycerides but also non–HDL-C, apolipoprotein B, and small dense LDL, have benefits for ASCVD prevention in subjects with hypertriglyceridemia. This evidence concerns the gene APOB and hypertriglyceridemia.